Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Axumin Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Multi-dose vial (30mL, 50mL)—1
Manufacturer
Generic Availability
NO
Mechanism of Action
Fluciclovine F 18 is a synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells. Fluciclovine F 18 is taken up to a greater extent in prostate cancer cells compared with surrounding normal tissues.
Axumin Indications
Indications
For positron emission tomography (PET) in males with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.
Axumin Dosage and Administration
Adult
See full labeling. Give 370MBq (10mCi) as an IV bolus inj. Initiate imaging 3–5mins post-inj.
Children
Not established.
Axumin Contraindications
Not Applicable
Axumin Boxed Warnings
Not Applicable
Axumin Warnings/Precautions
Warnings/Precautions
Have resuscitation equipment readily available. Risk for radiation exposure. Should only be used by trained and experienced physicians in the safe use and handling of radioactive materials to minimize radiation exposure. Risk for image misinterpretation and other errors. Not for use in females.
Axumin Pharmacokinetics
Elimination
Renal. Half-life: 109.7 minutes.
Axumin Interactions
Not Applicable
Axumin Adverse Reactions
Adverse Reactions
Inj site pain, erythema, dysgeusia; hypersensitivity reactions.
Axumin Clinical Trials
See Literature
Axumin Note
Not Applicable
Axumin Patient Counseling
See Literature
